CAMP4 Therapeutics CMO Yuri Maricich MD joined Jessica Brazill in a recent Rareatives article discussing the path toward developing the first potential treatment for SYNGAP1-related disorder.
Published
Signal category
Research & Knowledge
Quote
“Our CMO, Yuri Maricich MD MBA, MD, joined Jessica Brazill in this recent #Rareatives article for a conversation on the path toward developing the first potential treatment for #SYNGAP1-related disorder.”
— CAMP4 Therapeutics team
Company
CAMP4 Therapeutics
Advancing a pipeline of ASO-based, RNA-targeting therapeutics with the aim to restore healthy protein levels
- Industry
- Biotechnology Research
- Location
- Cambridge, US
- Company size
- 61 employees
At CAMP4 Therapeutics, we are pioneering a novel approach to programmable therapeutics. We combine a deep understanding of regulatory RNA and gene expression with a complementary and customizable oligonucleotide modality. Our platform’s proprietary insights enable us to harness the power of RNA to upregulate the expression of genes and unlock the potential to create treatments for hundreds of diseases affecting millions of patients. Join us at the forefront.
Founded 2016